The abrupt CEO change and complete shutdown of regenerative medicine R&D signal severe financial distress at a $13M market cap. Watch for a potential going-concern qualification in the next 20-F annual report and any further asset sales or financing needs to fund the rhCollagen supply business.
Price Chart
How similar events traded
Executive Summary
CollPlant announced the immediate replacement of CEO Yehiel Tal with Eran Rotem as part of a cost-reduction plan that includes discontinuing all regenerative medicine R&D activities. The company will continue producing and supplying recombinant human collagen (rhCollagen) and rhCollagen-based bioinks to partners and customers.
Key Facts
- CEO Yehiel Tal removed effective immediately as part of a cost-reduction plan
- Eran Rotem (Deputy CEO and CFO) appointed as CEO, retaining CFO role with unchanged compensation
- Company discontinuing all regenerative medicine research and development activities
- rhCollagen production and supply to partners, collaborators and customers will continue
- Tal resigned as Interim Chairman but remains on the board
- Market cap is $13M with a 7.0% normal daily move
Financial Impact
Discontinuation of all regenerative medicine R&D represents a fundamental strategic pivot; no dollar figures provided for cost savings or severance
Risk Factors
- Discontinuation of all regenerative medicine R&D eliminates the company's pipeline and growth prospects
- Abrupt CEO departure suggests deeper financial or strategic issues beyond the stated cost-reduction plan
- The company may need additional capital to fund ongoing rhCollagen operations without R&D prospects
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-114972 |
| Document: 0001213900-26-114972-index-headers.html | 0001213900-26-114972 |
| Document: 0001213900-26-114972-index.html | 0001213900-26-114972 |
| Document: 0001213900-26-114972.txt | 0001213900-26-114972 |
| Earnings Context (Synthetic; results releases only) | 0001213900-26-114972 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | 6-K | $4.19 | awaiting T+1 | awaiting T+1 | $4.11 (−1.91%) |
Nov 3, 2026 today | 6-K | $3.99 | awaiting T+1 | awaiting T+1 | $4.11 (+3.01%) |
Nov 2, 2026 1d ago | 6-K | $4.08 | awaiting T+1 | awaiting T+1 | $4.11 (−0.74%) |
Oct 29, 2026 6d ago | 6-K | $4.40 $4.14 | ▼ −6.02% | ▼ −4.25% | $4.11 (−6.59%) |
Oct 27, 2026 8d ago | 144 | $3.90 $3.95 | ▲ +1.28% | ▲ +0.94% | $4.11 (+5.38%) |
Oct 19, 2026 15d ago | 3 | $3.88 $3.76 | ▼ −3.22% | ▼ −3.75% | $4.11 (+5.93%) |
Oct 15, 2026 20d ago | 6-K | $3.68 $3.63 | ▲ +1.49% | ▲ +0.39% | $4.11 (−11.68%) |
Oct 9, 2026 25d ago | 6-K | $4.02 $3.91 | ▲ +2.74% | ▲ +2.72% | $4.11 (−2.24%) |
Oct 8, 2026 27d ago | SC 13G | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $4.11 (+3.53%) |
Oct 8, 2026 27d ago | SC 13D/A | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $4.11 (+3.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers